- Home
- OPFI vs OLMA Comparison
OPFI vs OLMA Comparison
Compare OPFI & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- OLMA
- Stock Information
- Founded
- OPFI 2009
- OLMA 2006
- Country
- OPFI United States
- OLMA United States
- Employees
- OPFI N/A
- OLMA N/A
- Industry
- OPFI Finance: Consumer Services
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- OLMA Health Care
- Exchange
- OPFI Nasdaq
- OLMA Nasdaq
- Market Cap
- OPFI 300.3M
- OLMA 299.7M
- IPO Year
- OPFI N/A
- OLMA 2020
- Fundamental
- Price
- OPFI $10.17
- OLMA $5.46
- Analyst Decision
- OPFI Buy
- OLMA Strong Buy
- Analyst Count
- OPFI 2
- OLMA 5
- Target Price
- OPFI $11.75
- OLMA $24.00
- AVG Volume (30 Days)
- OPFI 1.3M
- OLMA 440.3K
- Earning Date
- OPFI 08-06-2025
- OLMA 08-11-2025
- Dividend Yield
- OPFI 9.79%
- OLMA N/A
- EPS Growth
- OPFI N/A
- OLMA N/A
- EPS
- OPFI N/A
- OLMA N/A
- Revenue
- OPFI $320,831,000.00
- OLMA N/A
- Revenue This Year
- OPFI $116.69
- OLMA N/A
- Revenue Next Year
- OPFI $9.90
- OLMA N/A
- P/E Ratio
- OPFI N/A
- OLMA N/A
- Revenue Growth
- OPFI 31.26
- OLMA N/A
- 52 Week Low
- OPFI $3.93
- OLMA $2.86
- 52 Week High
- OPFI $17.73
- OLMA $13.93
- Technical
- Relative Strength Index (RSI)
- OPFI 46.36
- OLMA 54.42
- Support Level
- OPFI $10.11
- OLMA $5.54
- Resistance Level
- OPFI $10.76
- OLMA $5.85
- Average True Range (ATR)
- OPFI 0.47
- OLMA 0.30
- MACD
- OPFI 0.08
- OLMA -0.01
- Stochastic Oscillator
- OPFI 51.49
- OLMA 51.79
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.